• Curaleaf management commentary attributed third-quarter 2026 revenue growth of 11% to USD 352.65 million to retail expansion and stronger wholesale distribution.
• International revenue rose 28% to USD 58.7 million, driven by patient growth and flower and vape sales in Germany and Britain.
• Gross margin fell to 48% from 51%, reflecting changes in product mix, including the balance of wholesale versus retail sales.
• Operating expenses increased 9% to USD 167.53 million, primarily reflecting higher compensation costs and professional fees.
• Net loss narrowed to USD 32.72 million from USD 56.68 million, primarily reflecting a lower tax provision and improved discontinued operations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curaleaf Holdings Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.